Still, we have to acknowledge that there is a large proportion of people with a genetic variant in the ALPL gene and the biochemical signature of HPP who do not exhibit clinically relevant symptoms, and thus may be considered subclinical [52]. This evidence concerns the gene ALPL and hypophosphatasia.